Adenosine A2B Receptor Neurons

Overview

flowchart TD
    Adenosine_A2B_Receptor_Neurons["Adenosine A2B Receptor Neurons"]
    Adenosine_A2B_Receptor_Neurons["table"]
    Adenosine_A2B_Receptor_Neurons -->|"related to"| Adenosine_A2B_Receptor_Neurons
    style Adenosine_A2B_Receptor_Neurons fill:#81c784,stroke:#333,color:#000
    Adenosine_A2B_Receptor_Neurons["class"]
    Adenosine_A2B_Receptor_Neurons -->|"related to"| Adenosine_A2B_Receptor_Neurons
    style Adenosine_A2B_Receptor_Neurons fill:#81c784,stroke:#333,color:#000
    Adenosine_A2B_Receptor_Neurons["infobox"]
    Adenosine_A2B_Receptor_Neurons -->|"related to"| Adenosine_A2B_Receptor_Neurons
    style Adenosine_A2B_Receptor_Neurons fill:#81c784,stroke:#333,color:#000
    style Adenosine_A2B_Receptor_Neurons fill:#4fc3f7,stroke:#333,color:#000

Adenosine A2B Receptor Neurons
Name	Adenosine A2B Receptor Neurons
Type	Cell Type

The adenosine A2B receptor (A2BR, ADORA2B) is a G protein-coupled receptor that binds adenosine with low affinity and mediates cellular responses to elevated extracellular adenosine concentrations. Unlike the high-affinity A1 and A2A receptors, A2B receptor activation occurs primarily under pathological conditions where adenosine levels are elevated, such as ischemia, inflammation, or metabolic stress. This property positions A2B receptors as critical sensors of cellular distress and important modulators of neuroinflammatory and regenerative responses in neurodegenerative diseases.

Neurons expressing the A2B receptor represent a unique population with distinct functional properties. While A2B receptor expression is relatively low in the healthy central nervous system, it becomes dramatically upregulated under pathological conditions, making it a potential biomarker and therapeutic target in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. Understanding the role of A2B-expressing neurons provides insight into endogenous neuroprotective mechanisms and opportunities for pharmacological intervention.

Receptor Biology

Molecular Structure and Pharmacology

The adenosine A2B receptor is a 332-amino acid G protein-coupled receptor (GPCR) encoded by the ADORA2B gene located on chromosome 17p12-p11. Like all adenosine receptors (A1, A2A, A2B, A3), A2B possesses the classic seven transmembrane domain structure characteristic of GPCRs:

Transmembrane domains: Seven α-helices (TM1-TM7) spanning the plasma membrane
Extracellular loops: Three loops (ECL1-ECL3) involved in ligand binding
Intracellular loops: Three loops (ICL1-ICL3) coupling to G proteins
C-terminal tail: Intracellular domain involved in receptor desensitization and signaling

A2B receptor has the lowest affinity for adenosine among adenosine receptors, with an EC50 in the micromolar range (compared to nanomolar for A1 and A2A). This low affinity means A2B is preferentially activated under conditions of high adenosine, such as:

Ischemia and hypoxia
Inflammation and tissue injury
Metabolic stress
Intense neural activity

Agonists:

BAY 60-6583: Selective A2B agonist used experimentally
NECA (5’-N-ethylcarboxamidoadenosine): Non-selective adenosine analog
ATL-146e: A2B-selective agonist with potential therapeutic applications

Antagonists:

MRS1754: Selective A2B antagonist
PSB-603: Potent A2B antagonist
CVT-6883: A2B antagonist developed for pulmonary diseases
Alloxazine: Non-selective A2B antagonist

Signaling Pathways

A2B receptor couples primarily to Gs proteins, activating adenylate cyclase and increasing intracellular cAMP. However, it can also couple to Gq proteins, activating phospholipase C (PLC) pathways:

Gs-coupled signaling:

↑ cAMP → PKA activation
↑ CREB phosphorylation
Modulation of ion channel function
Regulation of gene transcription

Gq-coupled signaling:

↑ IP3 and DAG
Calcium release from intracellular stores
PKC activation
Activation of MAPK pathways

The dual coupling allows A2B receptors to mediate diverse cellular responses depending on cellular context and co-expressed proteins.

Receptor Regulation

Transcriptional regulation:

NF-κB-mediated upregulation during inflammation
HIF-1α stabilization under hypoxia
CREB-dependent transcription

Post-translational regulation:

Phosphorylation by GRK and PKA
β-arrestin recruitment and receptor internalization
Receptor trafficking to the cell surface

Desensitization:

Rapid desensitization via GRK-mediated phosphorylation
β-arrestin-dependent internalization
Long-term downregulation with chronic agonist exposure

Cellular Distribution in the CNS

Neuronal Expression

A2B receptor expression in neurons is relatively sparse under normal conditions but becomes more prominent in specific neuronal populations under pathological states:

Cortical neurons:

Layer 2/3 pyramidal neurons show A2B expression in human cortex
Interneurons, particularly parvalbumin-positive cells, express A2B
Expression increases in AD and related dementias

Hippocampal neurons:

CA1 pyramidal neurons exhibit A2B expression
Dentate gyrus granule cells show upregulation in epilepsy and AD
Hippocampal interneurons are A2B-positive

Subcortical nuclei:

Basal ganglia neurons express A2B, particularly in PD
Thalamic relay neurons show A2B immunoreactivity
Hypothalamic neurons, especially those involved in energy homeostasis

Brainstem neurons:

Locus coeruleus noradrenergic neurons express A2B
Raphe serotonin neurons show A2B regulation
Motor neurons in the spinal cord

Glial Expression

A2B receptor expression is more prominent in glial cells:

Astrocytes:

A2B is highly expressed in astrocytes, particularly in regions of injury
Astrocytic A2B mediates pro-inflammatory and protective responses
Regulates astrocyte proliferation and gliosis

Microglia:

Microglial A2B expression increases dramatically in neurodegenerative conditions
A2B signaling modulates microglial activation state
Can promote both pro-inflammatory and anti-inflammatory phenotypes

Oligodendrocytes:

A2B expression in oligodendrocyte precursors
Role in remyelination and oligodendrocyte regeneration
Involvement in white matter pathology

Signaling Mechanisms in Neurons

cAMP-Dependent Signaling

The primary signaling pathway for neuronal A2B receptors involves cAMP elevation:

Ion channel modulation:

Reduced potassium channel activity via PKA phosphorylation
Modulation of NMDA receptor function
Regulation of voltage-gated calcium channels

Gene expression:

CREB phosphorylation and transcriptional activation
Upregulation of neuroprotective genes
Anti-apoptotic signaling

Synaptic function:

Modulation of neurotransmitter release
Regulation of synaptic plasticity
Effects on long-term potentiation (LTP)

Calcium Signaling

A2B receptor coupling to Gq pathways enables calcium signaling:

IP3-mediated calcium release from endoplasmic reticulum
Activation of calcium-dependent kinases
Modulation of neuronal excitability
Regulation of gene transcription via calcium-dependent pathways

Cross-talk with Other Receptors

A2B receptors exhibit significant cross-talk with other signaling systems:

Adenosine receptors:

Cross-talk with A2A receptors (heterodimerization reported)
Antagonistic interaction with A1 receptors
Additive effects with A3 receptors

Other GPCRs:

Interaction with metabotropic glutamate receptors
Cross-talk with muscarinic acetylcholine receptors
Dopamine receptor interactions in the basal ganglia

Ionotropic receptors:

Modulation of NMDA receptor function
Interaction with GABA receptors
Regulation of AMPA receptor trafficking

Pathophysiology in Neurodegenerative Diseases

Alzheimer’s Disease

A2B receptor signaling has complex and context-dependent roles in AD:

Amyloid pathology:

A2B activation promotes amyloid-β clearance in cellular models
Enhances microglia-mediated phagocytosis
May reduce amyloid deposition in animal models

Tau pathology:

Limited evidence for direct A2B-tau interactions
Indirect effects through modulation of kinase/phosphatase activity

Neuroinflammation:

A2B has pro-inflammatory effects in early AD
Promotes cytokine production by microglia
May contribute to chronic neuroinflammation

Cognitive function:

A2B signaling affects hippocampal plasticity
Modulates memory consolidation
Some evidence for cognitive enhancement in animal models

Therapeutic implications:

Selective A2B agonists have been explored for AD
Concern about pro-inflammatory effects
Need for careful timing of intervention

Parkinson’s Disease

A2B receptors play significant roles in PD pathophysiology:

Dopaminergic neurons:

A2B expression increases in substantia nigra in PD
May provide neuroprotection against dopaminergic toxicity
Modulates mitochondrial function

Neuroinflammation:

Promotes microglial activation in PD
Contributes to chronic neuroinflammation
May exacerbate dopaminergic neuron loss

Locus coeruleus:

A2B expressed in noradrenergic neurons
May modulate norepinephrine release
Related to LC pathology in PD

Therapeutic potential:

A2B antagonists explored for anti-inflammatory effects
Combined A2A/A2B targeting considered
Need for more selective compounds

Amyotrophic Lateral Sclerosis

A2B receptor involvement in ALS is increasingly recognized:

Motor neurons:

A2B expression increases in spinal cord motor neurons in ALS
May affect excitotoxicity
Role in energy metabolism

Glial involvement:

Microglial A2B promotes neuroinflammation
Astrocytic A2B affects motor neuron survival
Oligodendrocyte A2B in white matter changes

Therapeutic approaches:

A2B antagonists as anti-inflammatory agents
Need for blood-spinal barrier penetration
Early intervention may be critical

Multiple Sclerosis and Demyelination

A2B receptors have particularly important roles in demyelinating diseases:

Oligodendrocyte precursors:

A2B promotes OPC proliferation
Enhances differentiation into mature oligodendrocytes
May promote remyelination

Immune modulation:

A2B affects T-cell function
Modulates B-cell activity
Reduces autoimmunity

Clinical potential:

A2B agonists for promoting remyelination
Combined immunomodulatory and regenerative effects
Currently experimental

Stroke and Ischemia

A2B receptors are particularly important in cerebral ischemia:

Ischemic cascade:

Adenosine levels rise dramatically during ischemia
A2B activation provides neuroprotective signals
Reduces infarct size in animal models

Mechanisms:

Anti-apoptotic signaling via cAMP/PKA
Anti-inflammatory effects
Promotion of angiogenesis
Enhancement of cerebral blood flow

Therapeutic window:

Preconditioning effects
Post-ischemic intervention potential
Time-limited neuroprotection

Functional Consequences of A2B Expression

Modulation of Neuronal Excitability

A2B receptor activation affects neuronal excitability through multiple mechanisms:

Potassium channels:

PKA-dependent phosphorylation reduces potassium currents
Increases neuronal firing frequency
May contribute to hyperexcitability

Calcium channels:

Voltage-gated calcium channel modulation
Effects on synaptic transmission
May influence synaptic plasticity

Synaptic transmission:

Modulates glutamate release
Affects GABAergic signaling
Bidirectional effects depending on brain region

Effects on Neuroplasticity

A2B signaling influences various forms of synaptic plasticity:

Long-term potentiation:

Facilitates LTP in hippocampal CA1
Requires cAMP/PKA signaling
May involve NMDA receptor modulation

Long-term depression:

Can facilitate LTD in some contexts
Dependent on Gq signaling pathways
Role in memory flexibility

Homeostatic plasticity:

A2B may participate in synaptic scaling
Modulates activity-dependent gene expression
Affects neuronal network stability

Neuroprotection and Survival

A2B receptor activation can provide neuroprotective effects:

Anti-apoptotic signaling:

cAMP/PKA pathway activation
CREB-mediated anti-apoptotic gene expression
Mitochondrial protection

Anti-oxidant effects:

Upregulation of antioxidant enzymes
Reduced ROS production
Mitochondrial function preservation

Metabolic support:

Enhanced glucose uptake
Improved energy metabolism
Astrocyte-neuron metabolic coupling

Inflammatory Modulation

A2B receptors have complex effects on neuroinflammation:

Pro-inflammatory effects:

Promotes cytokine production
Enhances microglial activation
May exacerbate chronic inflammation

Anti-inflammatory effects:

Can reduce some inflammatory responses
Promotes resolution of inflammation
Modulates adaptive immunity

Context dependence:

Effects depend on timing and duration
Early vs. late stages differ
Need for detailed mechanistic understanding

Therapeutic Approaches

A2B Agonists

Rationale:

Promote neuroprotection
Enhance amyloid clearance
Support remyelination
Provide anti-ischemic effects

Challenges:

Low receptor selectivity
Peripheral side effects
Timing of intervention critical

Clinical candidates:

BAY 60-6583 (preclinical)
ATL-146e (preclinical)
Various adenosine analogs under development

A2B Antagonists

Rationale:

Reduce neuroinflammation
Protect dopaminergic neurons
Modulate immune responses

Challenges:

Blood-brain barrier penetration
Selectivity over A2A
Chronic vs. acute effects

Clinical candidates:

MRS1754 (research use)
PSB-603 (research use)
CVT-6883 (pulmonary, not CNS-penetrant)

Adjunctive Therapies

A2B-targeting therapies may be combined with:

Dopaminergic therapies in PD
Anti-amyloid therapies in AD
Anti-glutamatergic approaches in ALS
Immunomodulatory therapies

Biomarkers and Diagnostic Applications

Imaging

PET ligands for A2B receptors under development
MRI approaches for A2B-related changes
Functional imaging of A2B-dependent processes

Fluid Biomarkers

CSF adenosine levels
A2B-dependent gene expression
Cytokine profiles reflecting A2B activity

Clinical Correlates

Disease severity and progression
Treatment response prediction
Biomarker combinations for patient stratification

Research Methods and Tools

Genetic Models

Adora2b knockout mice: Constitutive and conditional knockout lines available
Reporter mice: A2B-Cre driver lines for cell-type-specific manipulation
Humanized models: Expressing human A2B in mouse models

Pharmacological Tools

Radioligands: [3H]MRS1754 for receptor binding studies
Fluorescent ligands: For receptor visualization
Biophysical approaches: FRET, BRET for signaling studies

Experimental Approaches

Primary neuron cultures: Murine and human neurons
Organotypic brain slices: For circuit-level studies
In vivo imaging: Two-photon microscopy of A2B activity

Future Directions

Selective Compound Development

Improved A2B-selective agonists and antagonists
Brain-penetrant compounds
Compounds with optimal pharmacokinetics

Biomarker Development

Clinical-grade PET ligands
Fluid biomarker validation
Patient stratification markers

Clinical Translation

Target indication selection
Trial design considerations
Combination therapy approaches

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.